NASDAQ:ELOX

Eloxx Pharmaceuticals Stock Forecast, Price & News

$2.80

-0.02 (-0.71 %)

(As of 10/21/2020 12:00 AM ET)

Add

Compare

Today's Range

$2.74

Now: $2.80▼

$2.86

50-Day Range N/A

52-Week Range

$1.44

Now: $2.80▼

$8.16

Volume12,615 shs

Average Volume123,389 shs

Market Capitalization$112.39 million

P/E RatioN/A

Dividend YieldN/A

Beta2.55

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Eloxx Pharmaceuticals.

0.0 Community Rank

Outperform Votes
Eloxx Pharmaceuticals has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eloxx Pharmaceuticals has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Eloxx Pharmaceuticals and other stocks. Vote “Outperform” if you believe ELOX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ELOX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Eloxx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eloxx Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 33.40% of the stock of Eloxx Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 21.69% of the stock of Eloxx Pharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($0.98) to ($0.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eloxx Pharmaceuticals is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eloxx Pharmaceuticals is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eloxx Pharmaceuticals has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.13 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ELOX

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.eloxxpharma.com

Phone781 577 5300

Employees29

Debt

Debt-to-Equity Ratio0.43

Current Ratio3.62

Quick Ratio3.62

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.91 per share

Price / Book3.08

Profitability

EPS (Most Recent Fiscal Year)($1.34)

Net Income$-50,870,000.00

Net MarginsN/A

Return on Equity-144.83%

Return on Assets-86.63%

Miscellaneous

Outstanding Shares40,138,000

Market Cap$112.39 million

Next Earnings Date11/5/2020 (Confirmed)

OptionableOptionable

$2.80

-0.02 (-0.71 %)

(As of 10/21/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ELOX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.

Eloxx Pharmaceuticals (NASDAQ:ELOX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Eloxx Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eloxx Pharmaceuticals.

When is Eloxx Pharmaceuticals' next earnings date?

Eloxx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Eloxx Pharmaceuticals.

How can I listen to Eloxx Pharmaceuticals' earnings call?

Eloxx Pharmaceuticals will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.20) EPS for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.02.
View Eloxx Pharmaceuticals' earnings history.

Who are some of Eloxx Pharmaceuticals' key competitors?

Some companies that are related to Eloxx Pharmaceuticals include STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Auxly Cannabis Group (CBWTF), Pieris Pharmaceuticals (PIRS), Bioanalytical Systems (BASI), NanoViricides (NNVC), NanoViricides (NNVC), ProMIS Neurosciences (ARFXF), Cleveland BioLabs (CBLI), Inhibitor Therapeutics (INTI), HedgePath Pharmaceuticals (HPPI), AIkido Pharma (AIKI), Tenax Therapeutics (TENX) and Vitality Biopharma (VBIO).
View all competitors.

Who are Eloxx Pharmaceuticals' key executives?

Eloxx Pharmaceuticals' management team includes the following people:

Dr. Gregory Williams M.B.A., Ph.D., MBA, CEO & Director (Age 61, Pay $586.7k)
Dr. Silvia Noiman M.B.A., Ph.D., MBA, Founder & Director (Age 64, Pay $40k)
Mr. Neil S. Belloff Esq., COO, Gen. Counsel & Corp. Sec. (Age 60)
Mr. Stephen MacDonald, VP of Fin. & Accounting, Principal Accounting Officer and Treasurer (Age 49)
Ms. Barbara Ryan, Investor Relations Officer

What is Eloxx Pharmaceuticals' stock symbol?

Eloxx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ELOX."

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eloxx Pharmaceuticals' stock price today?

One share of ELOX stock can currently be purchased for approximately $2.80.

How big of a company is Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals has a market capitalization of $112.39 million. The company earns $-50,870,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. Eloxx Pharmaceuticals employs 29 workers across the globe.

What is Eloxx Pharmaceuticals' official website?

The official website for Eloxx Pharmaceuticals is www.eloxxpharma.com.

How can I contact Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals' mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company can be reached via phone at 781 577 5300 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings